RxDoctor Payments Data

Srilakshmi Pisati, MD

Internal Medicine · Cincinnati, OHNPI 1265494447

Payments from drug & device makers

$4,420in general payments, 2019–2025

Across 314 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • AstraZeneca$497
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$341
  • Pfizer$248
  • Novartis$239
  • GSK$227
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,33398%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,420 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$63,371
Medicare patients
133
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$169,012
JardianceEmpagliflozin120$114,328
TrulicityDulaglutide88$101,381
VraylarCariprazine Hcl57$83,751
EliquisApixaban105$81,945
LinzessLinaclotide106$76,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$65,031
JanuviaSitagliptin Phosphate62$59,066
MounjaroTirzepatide42$46,260
XareltoRivaroxaban60$45,426
DuleraMometasone/Formoterol114$40,091
FarxigaDapagliflozin Propanediol47$36,704
EntrestoSacubitril/Valsartan43$34,310
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$26,023
Breo ElliptaFluticasone/Vilanterol53$25,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$221$191,137179 claims
AbbVieVraylar, Linzess$969$160,636163 claims
Lilly USA, LLCTrulicity, Mounjaro$17$147,641130 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$133$143,870170 claims
MerckJanuvia, Dulera, Janumet$81$105,360187 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$227$101,706155 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Lokelma$497$95,214175 claims
PfizerEliquis$248$81,945105 claims
Johnson & JohnsonXarelto$13$45,42660 claims
NovartisEntresto$239$34,31043 claims
Sumitomo Pharma America, Inc.Gemtesa$187$16,17726 claims
Astellas Pharma US IncMyrbetriq$112$6,93815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →